NASDAQ:ALKS - Alkermes Stock Price, Forecast & News

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes Plc (NASDAQ:ALKS) posted its quarterly earnings data on Wednesday, October, 23rd. The company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.17. The business earned $255.24 million during the quarter, compared to analysts' expectations of $252.65 million. Alkermes had a negative net margin of 18.71% and a negative return on equity of 6.08%. Alkermes's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.07 earnings per share. View Alkermes' Earnings History.

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Alkermes.

9 equities research analysts have issued 1-year price objectives for Alkermes' stock. Their forecasts range from $20.00 to $34.00. On average, they anticipate Alkermes' share price to reach $26.44 in the next twelve months. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Price Targets for Alkermes.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

News coverage about ALKS stock has trended somewhat positive on Thursday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alkermes earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Alkermes.

Alkermes saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 5,250,000 shares, an increase of 10.5% from the December 15th total of 4,750,000 shares. Based on an average daily trading volume, of 1,580,000 shares, the days-to-cover ratio is presently 3.3 days. Currently, 3.4% of the shares of the stock are sold short. View Alkermes' Current Options Chain.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Netflix (NFLX), AbbVie (ABBV), Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Starbucks (SBUX), Gilead Sciences (GILD), Pfizer (PFE), Cisco Systems (CSCO) and Intel (INTC).

Alkermes' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.23%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Nisa Investment Advisors LLC (0.00%) and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.00%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, James M Frates, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.

ALKS stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA. View Insider Buying and Selling for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $18.58.

Alkermes has a market capitalization of $2.93 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.

The official website for Alkermes is http://www.alkermes.com/.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]